A qualitative study explores how these drugs are impacting these patients’ lives, while digging deeper into the possibility of deprescribing, with insight from primary care physicians.
Data show that 30% of Americans 65 years of age or older have experienced chronic pain, with more than 10% indicating that high-impact discomfort is impacting their activities.1 As a potential solution, primary care physicians (PCPs) may prescribe opioids, which can lead to complications such as addiction, sedation, and death from an unintentional overdose; television shows such as Dopesick and Painkiller have also put a spotlight on the ravages of the opioid epidemic.
In fact, though representing the general population, the Centers for Disease Control and Prevention reports that from 1999-2021, nearly 645,000 people died from an overdose involving any opioid.2
Although much of the garnered attention revolves around younger adults, more than 15% of those aged 65 years or older had filled an opioid prescription in 2019, and 5% were given long-term opioids. A study published in JAMA Network Open1 sought to dig into these individuals’ experiences with reducing long-term opioid use, along with PCPs’ thoughts on deprescribing.
Investigators started off the qualitative study by conducting 45-minute interviews with 29 patients and 18 PCPs at a Boston-area health system. The patients were to have been prescribed long-term opioids—which is considered at least three prescriptions for 28-day supplies during the prior 180 days—between Sept. 15, 2022, and April 26, 2023.
Patients were asked about their experiences using opioids and discussing these medications with their PCPs, while the PCPs were interviewed about their experiences prescribing and deprescribing opioids to older adults.
Of the 29 participating patients, the mean [SD] age, was 72 [5] years, while 19 were female [66%]. Regarding the PCPs, 18 of them were younger than 50 (12 [67%]); 10 were female [56%]; and 14 were located at an academic practice [78%].Participants revealed to the investigators that conversations between PCPs and patients on opioid use for chronic pain were normally quite difficult, while any discussion surrounding deprescribing and opioid risks were uncommon.
Among the patient and PCP interviews, there were three main themes that arose:
However, there were differing opinions on risks of opioids, as patients referenced addiction and PCPs discussed adverse drug events. The deprescribing conversations were not beneficial, being that the differing viewpoints made it difficult to have a productive conversation. Essentially, patients believed that deprescribing was usually unnecessary unless an adverse event took place, given that many patients had prior negative experiences with tapering or “weaning off.” The PCPs noted that there were gaps in knowledge on how to properly taper, a lack of clinical access to monitor patients during tapering, and concerns surrounding patient resistance.
As a result, the authors concluded that “…PCPs and older adults viewed opioid use as an effective last resort for treating chronic pain and expressed discordant views on the risks of opioids and reasons opioid deprescribing is often unsuccessful. Safely reducing opioid use among older adults with chronic pain is likely to require the development of materials to foster more informed conversations on the benefits and harms of opioids as well as payment and policy interventions to support the time and teams needed for deprescribing opioids.”
References
1. Anderson TS, Wang BX, Lindenberg JH, Herzig SJ, Berens DM, Schonberg MA. Older Adult and Primary Care Practitioner Perspectives on Using, Prescribing, and Deprescribing Opioids for Chronic Pain. JAMA Netw Open. 2024;7(3):e241342. doi:10.1001/jamanetworkopen.2024.1342
2. Understanding the Opioid Overdose Epidemic. Centers for Disease Control and Prevention. https://www.cdc.gov/opioids/basics/epidemic.html
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.